Clinical trial
Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three…
NCT00192374 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00192374 |
|---|---|
| Title | Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children |
| Official title | A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase III, Multicenter Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B,Live, Cold-Adapted (CAIV-T) in Healthy Children |
| Lead sponsor | MedImmune LLC, Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological |
| Interventions | CAIV-T, Liquid |
| Enrollment | 1,920 |
| Start date | Feb 1, 2002 |
| Completion | Nov 1, 2002 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 3, 2006 |
| Countries | Philippines, Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: